knowledge regarding diagnosis and treatment. Further, we report on a case of a fatal SP-B deficient infant.
Case Report
We report on a male neonate of 40 weeks' gestational age and 3.260-g birth weight, born to a 41-year-old mother. Parents were Caucasian and not related. This was the second pregnancy that proceeded uneventful. Amniocentesis was performed showing a normal male karyotype. The boy was born by caesarean section and initially presented with a weak cry, shallow breathing, hypotonia, and peripheral cyanosis.
Following bag-mask ventilation for 1 minute, the infant's breathing improved and the skin turned rosy. Subsequently, nasal continuous positive airway pressure (CPAP) was initiated resulting in prompt adaptation. Apgar scores were 7/10/10 at 1/ 5/10 minutes, respectively. Body length (52 cm) and head circumference (35 cm) were within normal ranges. Within the first hours of life tachy-and dyspnea increased and oxygen demand was increasing (FiO 2 0.3-0.5), whereas auscultation was unremarkable. At the age of 4 hours the infant was transferred to the neonatal intensive care unit (NICU) presenting with tachypnea (RR 70/min), pale skin, expiratory wheezing, and respiratory distress. SpO 2 was 93% at FiO 2 of 0.3. Chest X-ray showed mild diffuse infiltrations in both lungs (►Fig. 1). Laboratory findings revealed respiratory acidosis (PaCO 2 56 mm Hg). On the third day of life, mechanical ventilation was initiated because of worsened respiratory status, FiO 2 of 0.7, and PaCO 2 of 68 mm Hg. Chest X-ray revealed reduced lung volume and reticular infiltrations with positive air bronchogram. Surfactant replacement therapy (100 mg/kg body weight porcine surfactant [Curosurf, Chiesi Pharmaceuticals, Vienna, Austria]) resulted in acute improvement of oxygenation (reduction of FiO 2 to 0.4). However, within the following hours oxygen demand increased again. Within the first week of life FiO 2 ranged between 0.5 and 0.7. A 6-day course of methylprednisolone was unsuccessful. Congenital heart disease was excluded by echocardiography.
High-frequency oscillatory ventilation (HFOV) in combination with inhaled nitric oxide, as well as repeated surfactant supplementation and subsequent conventional mechanical ventilation, resulted in solely intermittent respiratory improvement and oxygen demand persisted at FiO 2 of 0.4 to 0.5. As far as surfactant dysfunction disorder was suspected, SP gene analysis from a blood sample was performed (University Hospital of Karlsruhe, Germany). Genetic analysis revealed SP-B deficiency caused by a homozygous C248X (p.Cys248Term, c.758C > A, TGC > TGA) mutation on exon 7 of the SP-B gene. Tracheotomy was performed at day 50 of life (see ►Fig. 2 showing chest X-ray). Lung transplant in case of worsening respiratory situation was declined by the parents. At the age of 92 days the boy died due to respiratory failure. Parents declined further investigations regarding possible heterozygosity.
Surfactant: Components and Metabolism
Surfactant proteins (SPs) play an important role in metabolism, structure, and function of surfactant. Surfactant contains the four known surfactant associated proteins: SP-A, SP-B, SP-C, and SP-D, which are synthesized and secreted by alveolar type II cells and are classified into hydrophobic (SP-B and SP-C) and hydrophilic (SP-A and SP-D) proteins.
10 SPs are well characterized regarding the respective genes, amino acid compositions, and messenger RNA (mRNA) sequences. Fig. 1 Early chest X-ray. Fig. 2 Chest X-ray after tracheotomy. Subsequently, affected children were found to be homozygous for a frameshift mutation being responsible for the lack of SP-B, constituting SP-B deficiency as basis of the infant's disease. 14 The same mutation was also found in three other infants unrelated to those described earlier, who had died from similar lung disease. These findings indicated the mutation found to be relatively common for this disease. The mutation involves the substitution of three bases for one in exon 4 of the gene, corresponding to codon 121 of the SP-B mRNA, and has been termed 121ins2 mutation for the net two base-pair insertion. 
10,40

Epidemiology
The population frequency of SP-B deficiency is currently unknown. However, an incidence of 1 in 1 million live births is estimated for the United States. 1 The c.397delCinsGAA
(121ins2) mutation is represented by an allele frequency of 1 per 1,000 to 3,000 individuals. 1-3 However, SP-B deficiency constituting a very rare disease might be underdiagnosed due to phenotypic variability and lack of awareness.
Clinical Presentation
Affected infants present well right after birth, showing no symptoms that might lead to the suspicion of SP-B deficiency. Hours after birth infants develop symptoms of surfactant deficiency, including tachypnea, grunting, retractions, nasal flaring, increased oxygen demand, and gray pallor. Blood gas analysis shows acidosis, hypoxemia, and hypercarbia. Radiographic findings show reticulogranular patterns with positive air bronchogram, increasing lung opacification, and reduced lung volume.
6
Respiratory failure is associated with the need for mechanical ventilation, HFOV, inhaled nitric oxide, or even extracorporeal membrane oxygenation (ECMO). However, these measures and surfactant replacement therapy result in only transient improvement of the respiratory condition.
In contrast, very few infants appear to have milder respiratory symptoms, with chest X-rays and clinical picture being consistent with more benign diagnoses such as transient tachypnea of the newborn. 5 Milder disease allowing prolonged survival has been observed in few children with mutations that allow for some residual SP-B production, and has been termed partial SP-B deficiency. is predominantly associated with infection whereas long-term mortality is predominantly due to bronchiolitis obliterans and infections, as well as lymphoproliferative malignancy.
53,56
However, these results do not appear to be caused by SP-B deficiency but rather by lung transplant itself. 53, 56 Lung transplantation is associated with life-long immunosuppression therapy, lung denervation, and the possibility to develop SP-B antibodies. 41, 56, 57 However, SP-B antibody production does not appear to be associated with poorer outcome. 56 Side effects and risks of life-long immunosuppressive therapy, as well as the need for close and consistent follow-up, the risks of complications, such as graft-versus-host disease, recurrent infections, and hospitalization all must be considered and discussed extensively with the parents.
39,57,58
Future Aspects SP-B deficiency might be an ideal candidate for gene therapy because it constitutes a monogenic defect and is inherited recessively. So far, adenoviral vectors have shown potential to deliver SP-B complementary DNA (cDNA) to animal lungs. 59, 60 Gene therapy might be an approach for future curative therapies, but as compared with gene therapy in cystic fibrosis currently remains target to research.
Conclusion
Although knowledge on underlying genetic variations constantly increases and genetic testing as well as gene therapy is frequently progressing, SP-B deficiency still remains a very rare and usually fatal disorder primarily affecting term infants. Response to interventions such as exogenous surfactant administration and high-dose corticosteroids are only temporary and infants usually die within the first year of life.
If an infant survives bridging to lung transplant-up to now 16 cases have been reported-this reflects the only curative 
